evidence table
Quercetin Skin Randomized Trial Evidence Table
Structured evidence table for Quercetin Skin Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Quercetin Skin Randomized Trial | Figure 1 Thus, in the present review we aimed to summarize the preclinical and clinical evidence of selected nutraceuticals, focusing on biotin, flavonoids especially luteolin, folic acid, Huperzine A, Lion’s mane, olive oil polyphenols (oleuropein and hydroxytyrosol [HT]), and palmitoylethanolamide (PEA). | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Quercetin Skin Randomized Trial | The present narrative review highlights current mechanistic insights, as well as evidence from experimental and clinical studies regarding their potential roles in supporting cognitive function, modulating neuroinflammation, and mitigating neurodegenerative processes. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Quercetin Skin Randomized Trial | It should be noted that the present work consists of a review and not a dosing guideline. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Quercetin Skin Randomized Trial | 1 1 Brain health is a multidimensional and evolving concept that is difficult to evaluate and quantify []. | 3 | Venetsanaki Vasiliki (2026) | Natural Molecules for Brain Health and Resilience |
| Quercetin Skin Randomized Trial | Systemic corticosteroid therapy effectively reduces recurrence rates; however, the severe adverse effects associated with long-term systemic corticosteroid use may outweigh the benefits for RAS patients () (). | 3 | Kong Xiangran (2026) | Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems |
| Quercetin Skin Randomized Trial | Notably, the role of local anesthetics (such as lidocaine) in RAS treatment is currently limited to symptomatic pain relief; there is insufficient evidence to suggest that they can alter disease progression, promote ulcer healing, or prevent recurrence (). | 3 | Kong Xiangran (2026) | Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems |
| Quercetin Skin Randomized Trial | Topical application of antibiotics, including tetracyclines (e.g., doxycycline, minocycline) and penicillin preparations, can result in lower pain scores, smaller ulcers, and a significant reduction in the healing cycle (). | 3 | Kong Xiangran (2026) | Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems |
| Quercetin Skin Randomized Trial | Epidemiological studies indicate a prevalence ranging from 5% to 66% across different countries (). | 3 | Kong Xiangran (2026) | Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems |
Source documents